TP53 and sarcoma: They include targeting and increased degradation of wild-type p53 by viral antigens in the case of cervical and oral cancers caused by oncogenic HPV forms [6] or over-expression of MDM2/MDM4 and degradation of p53 in several cancers including sarcomas and melanomas [7–9].